bioRxivCell BiologyPreprint
Modeling Endothelial Dysfunction in Idiopathic Pulmonary Fibrosis: Bridging Mechanistic Insights and Translational Applications
Annalena Branz, Irina ShalashovaiD, Anastasia M. Funk, Tarek Gensheimer, Agnieszka Wytyk, Susanne L. WespeliD, Jochen Drescher, Christoph H. MayriD, Lavinia NeubertiD, Jan C. KampiD, Mark KühneliD, Danny David JonigkiD, Manfred FrickiD, Muriel LizéiD
Abstract
The alveolus, the lungs primary gas exchange unit, relies on tightly coordinated interactions between epithelial and endothelial layers. In idiopathic pulmonary fibrosis (IPF), a progressive interstitial lung disease, this architecture is profoundly disrupted. While epithelial and mesenchymal compartments have been extensively studied, the role of pulmonary microvascular endothelial cells (PMVECs) in IPF pathogenesis remains underexplored. Here, we characterize PMVEC alterations in IPF using single-cell RNA sequencing and spatial transcriptomics, identifying subtype-specific markers and demonstrating their progressive loss in fibrotic lungs. To model endothelial dysfunction, we established robust protocols for isolating and culturing primary human ECs and applied a pharmacologically relevant cytokine cocktail (IPF-RC) that mimics the IPF microenvironment. IPF-RC exposure induced hallmark features of endothelial injury, including VE-cadherin loss, increased ICAM1/VCAM1 signaling, impaired barrier integrity, and reduced wound healing and angiogenic capacity. To address the need for translational tools in drug discovery, we optimized and validated a suite of functional, scalable test systems and their endpoints using both primary and commercial endothelial cells. These mechanistic assays reliably recapitulate fibrotic endothelial injury and enable quantitative assessment of therapeutic interventions. Notably, treatment with a cAMP analog partially restored endothelial function, supporting the utility of these models for regenerative and pharmacological screening. Our findings position PMVECs as active participants in IPF progression and present novel, scalable test systems that bridge mechanistic insight with translational application. These models offer a valuable platform for identifying endothelial-targeted therapies aimed at restoring alveolar capillary integrity in fibrotic lung disease.
- organism: human
- assay: scRNA-seq
- assay: spatial transcriptomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- ACKR1-expressing venous endothelial cells establish a pro-fibrotic niche in pulmonary fibrosis
Konstantinos Kontodimas, Ahmed Raslan, … Giovanni Ligresti·bioRxiv·Aug 3, 2026
- Engineering a 3D Lung Co-culture Platform to Model Epithelial-Fibroblast Interactions in Pulmonary Fibrosis
Mejalaa Mega Jayaseelan, Aleksander Skardal, … Megan N. Ballinger·bioRxiv·May 13, 2026
- Transcriptomics, metabolomics and lipidomics of chronically injured alveolar epithelial cells reveals similar features of IPF lung epithelium
W. Roque, K. Cuevas-Mora, … F. Romero·bioRxiv·May 8, 2020
- Modeling of Aberrant Epithelial Reprogramming in Idiopathic Pulmonary Fibrosis using Human Induced Pluripotent Stem Cell-derived Alveolar Organoids
V. Ptasinski, S. J. Monkley, … L. A. Murray·bioRxiv·Jun 15, 2022
- Recapitulating idiopathic pulmonary fibrosis related alveolar epithelial dysfunction in an iPSC-derived air-liquid interface model
E. Schruf, V. Schroeder, … J. P. Garnett·bioRxiv·Nov 4, 2019
- Modeling cell-cell interactions to advance drug discovery in Idiopathic Pulmonary Fibrosis
Chandani Sen, Justin Langerman, … Brigitte N. Gomperts·bioRxiv·Jun 25, 2026